Đa hình rs1799971 gen OPRM1 và một số yếu tố liên quan trên người bệnh nghiện chất dạng thuốc phiện điều trị Methadone thay thế

Abstract

Methadone is an opioid receptor agonist used as substitution therapy for patients with opioid-dependence. Within a multipronged treatment strategy, including evidence-based approaches, genetic characteristics may provide important data related to treatment outcomes. The OPRM1 gene which encodes the µ-opioid receptor (MOR, MOP) – the primary active site of methadone has been extensively studied for its role in vulnerability to substance use disorders and treatment response. This study analyzed OPRM1 gene polymorphysm in 200 patients undergoing methadone maintenance therapy to determine genotype characteristics and related factors in opioid-dependent patient, thereby contributing additional genetic data to the population. In the study population, the G allele frequency was 41.8%, and the genotype distribution was in Hardy–Weinberg equilibrium (χ² = 0.11). In the multivariable regression model, we analyzed factors associated with methadone dose and Alcohol Use Disorders Identification Test – Consumption (AUDIT-C) scores; the analysis showed no clinical factor or OPRM1 genotypes with statistically significant associations (p > 0.05). However, the OPRM1 GG genotype was significantly negatively associated with tobacco use disorder compared with the AA genotype (Coef = −0.893; p = 0.005).